Physician profile
Jack B Cohen
NPI 1134188279
$4,816.51
in general payments reported to CMS, 2019-2025
24 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2022: $265 · 2023: $1,055 · 2024: $1,765 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $618.95 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $578.92 | 2023-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $466.25 | 2024-2025 | |
| Genzyme Corporation | $463.88 | 2022-2025 | |
| Lilly USA, LLC | $460.91 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $392.09 | 2023-2025 | |
| Ucb, INC. | $360.03 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $292.25 | 2022-2025 | Otezla, Otezla |
| Biofrontera INC. | $248.96 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $236.37 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $157.37 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $112.11 | 2024 | Zoryve |
| Leo Pharma INC. | $98.98 | 2023-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $50.12 | 2024 | Ycanth |
| Incyte Corporation | $47.72 | 2023-2024 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.78 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $31.04 | 2023-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.87 | 2025 | Spevigo |
| Journey Medical Corporation | $27.06 | 2023 | |
| Kyowa Kirin, INC. | $25.80 | 2024 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $24.67 | 2025 | |
| Almirall LLC | $19.95 | 2023 | Klisyri |
| Lnhc, INC | $15.81 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $12.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.